<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients</title>
				<funder ref="#_K95Yvp6">
					<orgName type="full">Sidaction</orgName>
				</funder>
				<funder>
					<orgName type="full">Agence nationale de recherches sur le sida et les he ´patites virales [ANRS</orgName>
				</funder>
				<funder ref="#_guAkcAM">
					<orgName type="full">CHU of Bordeaux</orgName>
				</funder>
				<funder ref="#_Y66brWp">
					<orgName type="full">ANRS</orgName>
				</funder>
				<funder>
					<orgName type="full">Action</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2017-01-03">January 3, 2017</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Marie-Quitterie</forename><surname>Picat</surname></persName>
							<email>marie-quitterie.picat@isped.u-bordeaux2.fr</email>
							<affiliation key="aff0">
								<orgName type="department">Centre INSERM U1219</orgName>
								<orgName type="institution">Bordeaux Population Health</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Univ. Bordeaux</orgName>
								<orgName type="institution" key="instit2">ISPED</orgName>
								<address>
									<region>Bordeaux</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Service d&apos;Information Me ´dicale</orgName>
								<orgName type="department" key="dep2">CHU de Bordeaux -Po ˆle de Sante ´Publique</orgName>
								<orgName type="institution">USMR</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">INRIA, Team SISTM</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Vaccine Research Institute-VRI</orgName>
								<address>
									<settlement>Ho ˆpital</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Isabelle</forename><surname>Pellegrin</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Laboratoire d&apos;Immunologie-Immunoge ´ne ´tique</orgName>
								<orgName type="institution">CHU Bordeaux</orgName>
								<address>
									<addrLine>Po ˆle de Biologie</addrLine>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Juliette</forename><surname>Bitard</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Laboratoire d&apos;Immunologie-Immunoge ´ne ´tique</orgName>
								<orgName type="institution">CHU Bordeaux</orgName>
								<address>
									<addrLine>Po ˆle de Biologie</addrLine>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Linda</forename><surname>Wittkop</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre INSERM U1219</orgName>
								<orgName type="institution">Bordeaux Population Health</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Univ. Bordeaux</orgName>
								<orgName type="institution" key="instit2">ISPED</orgName>
								<address>
									<region>Bordeaux</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Service d&apos;Information Me ´dicale</orgName>
								<orgName type="department" key="dep2">CHU de Bordeaux -Po ˆle de Sante ´Publique</orgName>
								<orgName type="institution">USMR</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">INRIA, Team SISTM</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Ce</forename><surname>´cile Proust-Lima</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre INSERM U1219</orgName>
								<orgName type="institution">Bordeaux Population Health</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Univ. Bordeaux</orgName>
								<orgName type="institution" key="instit2">ISPED</orgName>
								<address>
									<region>Bordeaux</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Benoı</forename><surname>ˆt Liquet</surname></persName>
							<affiliation key="aff6">
								<orgName type="laboratory">Laboratoire de Mathe ´matiques et de leurs Applications</orgName>
								<address>
									<addrLine>Universite ´de Pau et des Pays de l&apos;Adour</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff7">
								<orgName type="department">ARC Centre of Excellence for Mathematical and Statistical Frontiers</orgName>
								<orgName type="laboratory">UMR CNRS 5142</orgName>
								<orgName type="institution">Queensland University of Technology (QUT)</orgName>
								<address>
									<settlement>Pau Brisbane</settlement>
									<country>France Australia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jean-Franc ¸ois</forename><surname>Moreau</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Laboratoire d&apos;Immunologie-Immunoge ´ne ´tique</orgName>
								<orgName type="institution">CHU Bordeaux</orgName>
								<address>
									<addrLine>Po ˆle de Biologie</addrLine>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">Univ. Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">11 Service de Me ´decine Interne et maladies Infectieuses</orgName>
								<orgName type="laboratory">UMR 5164</orgName>
								<orgName type="institution">CNRS</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Fabrice</forename><surname>Bonnet</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre INSERM U1219</orgName>
								<orgName type="institution">Bordeaux Population Health</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">Univ. Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Blanco</surname></persName>
							<affiliation key="aff5">
								<orgName type="laboratory">Laboratoire d&apos;Immunologie-Immunoge ´ne ´tique</orgName>
								<orgName type="institution">CHU Bordeaux</orgName>
								<address>
									<addrLine>Po ˆle de Biologie</addrLine>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="institution">Univ. Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff9">
								<orgName type="department">11 Service de Me ´decine Interne et maladies Infectieuses</orgName>
								<orgName type="laboratory">UMR 5164</orgName>
								<orgName type="institution">CNRS</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Rodolphe</forename><surname>Thie ´baut</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Centre INSERM U1219</orgName>
								<orgName type="institution">Bordeaux Population Health</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution" key="instit1">Univ. Bordeaux</orgName>
								<orgName type="institution" key="instit2">ISPED</orgName>
								<address>
									<region>Bordeaux</region>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Service d&apos;Information Me ´dicale</orgName>
								<orgName type="department" key="dep2">CHU de Bordeaux -Po ˆle de Sante ´Publique</orgName>
								<orgName type="institution">USMR</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="institution">INRIA, Team SISTM</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution">Vaccine Research Institute-VRI</orgName>
								<address>
									<settlement>Ho ˆpital</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Aquitaine</forename><surname>Cohort</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Service d&apos;Information Me ´dicale</orgName>
								<orgName type="department" key="dep2">CHU de Bordeaux -Po ˆle de Sante ´Publique</orgName>
								<orgName type="institution">USMR</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Henri</forename><surname>Mondor</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Cre</forename><surname>´teil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">De</forename><surname>Witte</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Dondia</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Dupon</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Dupont</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Duffau</surname></persName>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Dutronc</surname></persName>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Farbos</surname></persName>
						</author>
						<author>
							<persName><forename type="first">I</forename><surname>Faure</surname></persName>
						</author>
						<author>
							<persName><forename type="first">V</forename><surname>Gaborieau</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Y</forename><surname>Gerard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Greib</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Hessamfar-Joseph</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Y</forename><surname>Imbert</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Lacoste</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Lataste</surname></persName>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Lazaro</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Malvy</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><surname>Marie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Mechain</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Meraud</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Mercie</surname></persName>
						</author>
						<author>
							<persName><forename type="first">E</forename><surname>Monlun</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Morlat</surname></persName>
						</author>
						<author>
							<persName><forename type="first">D</forename><surname>Neau</surname></persName>
						</author>
						<author>
							<persName><forename type="first">A</forename><surname>Ochoa</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pellegrin</surname></persName>
						</author>
						<author>
							<persName><forename type="first">M</forename><surname>Pillot-Debelleix</surname></persName>
						</author>
						<author>
							<persName><forename type="first">T</forename><surname>Pistone</surname></persName>
						</author>
						<author>
							<persName><roleName>MC</roleName><forename type="first">I</forename><surname>Raymond</surname></persName>
						</author>
						<author>
							<persName><forename type="first">P</forename><surname>Receveur</surname></persName>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Rispal</surname></persName>
						</author>
						<author>
							<persName><forename type="first">S</forename><surname>Sorin</surname></persName>
						</author>
						<author>
							<persName><surname>Tchamgoue</surname></persName>
						</author>
						<author>
							<persName><forename type="first">C</forename><surname>Valette</surname></persName>
						</author>
						<author>
							<persName><roleName>MO</roleName><forename type="first">M</forename><forename type="middle">A</forename><surname>Vandenhende</surname></persName>
						</author>
						<author>
							<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Vareil</surname></persName>
						</author>
						<author>
							<persName><forename type="first">H</forename><surname>Viallard</surname></persName>
						</author>
						<author>
							<persName><forename type="first">G</forename><surname>Wille</surname></persName>
						</author>
						<author>
							<persName><surname>Wirth</surname></persName>
						</author>
						<author>
							<affiliation key="aff10">
								<orgName type="institution">CHU de Bordeaux</orgName>
								<address>
									<settlement>Bordeaux</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<orgName type="institution">University of Cape Town</orgName>
								<address>
									<country key="ZA">SOUTH AFRICA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2017-01-03">January 3, 2017</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1371/journal.pone.0169164</idno>
					<note type="submission">Received: August 18, 2016 Accepted: December 13, 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1" ident="GROBID" when="2025-10-28T23:00+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Members of the ANRS CO3 Aquitaine cohort study group are: Coordination: F. Bonnet, F. Dabis</term>
					<term>Scientific committee: F. Bonnet, S. Bouchet, D. Breilh, G. Chêne, F. Dabis, M. Dupon, H. Fleury, V. Gaborieau, D. Lacoste, D. Malvy, P. Mercie ´, P. Morlat, D. Neau, I. Pellegrin, JL. Pellegrin, S. Reigadas, S. Tchamgoue ´</term>
					<term>Epidemiology and Methodology: M. Bruyand, G. Chêne, F. Dabis, C. Fagard, S. Lawson-Ayayi, L. Richert, R. Thie ´baut, L. Wittkop</term>
					<term>Infectious Diseases and Internal Medicine: K. Andre ´, F. Bonnet, N. Bernard, O. Caubet, L. Caunègre, C. Cazanave, J. Ceccaldi, I. Chossat, C. Courtault, FA. Dauchy, S JF. Moreau, I. Pellegrin</term>
					<term>Virology: H. Fleury, ME. Lafon, S. Reigadas, P. Trimoulet. Pharmacology: S. Bouchet, D. Breilh, F. Haramburu, G. Miremont-Salame ´</term>
					<term>Data collection, Project Management and Statistical Analyses: MJ. Blaizeau, I. Crespel, M. Decoin, S. Delveaux, F. Diarra, C. D&apos;Ivernois, C. Hanappier, D. Lacoste, S. Lawson-Ayayi, O. Leleux, F. Le Marec, E. Lenaud, J. Mourali, E. Pernot, A. Pougetoux, B. Uwamaliya-Nziyumvira, A. Tsaranazy, A. Valdes</term>
					<term>IT department and eCRF development: V. Conte, I. Louis, G. Palmer, V. Sapparrart, D. Touchard</term>
					<term>Centre for Biological Ressources-CHU de Bordeaux: C. Le Scanf-Terrien, I. Pellegrin</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Objectives</head><p>To unravel the complex relationships between cytomegalovirus-induced-, autoimmuneinduced responses, microbial translocation and chronic immune activation (CIA) in successfully treated HIV-infected patients and to explore the mediating role of alpha-interferon in these processes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Design</head><p>Cross-sectional study nested in the ANRS CO3 Aquitaine Cohort, a prospective hospitalbased cohort of HIV-1-infected patients in South-Western France.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>Patients initiated antiretroviral therapy between 2005 and 2008 and were treated with sustained virological suppression for at least two years. CIA was defined by the percentage of HLA-DR+/CD38+ among CD8+T-cells. Integrative analyses were performed using structural equation modelling (SEM).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p>The main analysis was performed in 57 HLA-A*0201 positive patients, due to availability of percentages of actin-, vimentin-, lamin-specific CD8+T-cells (HLA-A2-restricted tests) to further characterize autoimmune response. Cytomegalovirus-induced response was assessed by Quantiferon and pp-65 ELISPOT. SEM revealed a direct effect of cytomegalovirus-</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Immune activation is a leading factor for human immunodeficiency virus (HIV) disease progression <ref type="bibr" target="#b0">[1,</ref><ref type="bibr" target="#b1">2]</ref>. The persistence of immune activation is associated with both acquired immunodeficiency syndrome (AIDS) and non-AIDS comorbidities <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref><ref type="bibr" target="#b5">[6]</ref> in patients under successful antiretroviral therapy with long-term virological suppression. Noteworthy, chronic type I alpha-interferon (IFN-α) is a hallmark in chronic activation and has been reported as a factor influencing disease progression in persistent infections <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref>, including HIV <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref>. The mechanisms driving chronic immune activation and type I interferon secretion are multifactorial and are not completely understood <ref type="bibr" target="#b12">[13]</ref>. Cytomegalovirus (CMV) and microbial translocation have been proposed as triggering factors for persistent immune activationassociated with HIV-1 infection <ref type="bibr" target="#b13">[14]</ref>. Microbial translocation and associated biomarkers, e.g. sCD14 and circulating plasma lipopolysaccharide <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref>, have been found to be implicated in the generation and maintenance of chronic immune activation. CMV is highly prevalent in HIV patients and may reactivate more frequently <ref type="bibr" target="#b17">[18]</ref>. Indeed, HIV disrupts the balance between the host and coinfecting or dormant microbes, worsening control of these potential pathogens. HIV-infected adults are more likely to have subclinical bursts of CMV replication compared to the general population. CMV reactivation and replication begin due to a progressive loss of immune function, and, in particular, due to a loss of cell-mediated immunity. Increased CMV-specific antibodies and/or T cells have been associated with atherosclerosis <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b19">20]</ref> and impaired CD4 T-cell reconstitution <ref type="bibr" target="#b17">[18]</ref> in HIV-infected patients on cART. Altogether, these data suggest that CMV coinfection may be a driver of persistent immune activation. Indeed, a randomized clinical trial with valgancyclovir in CMV-seropositive cARTtreated patients (n = 30) found that both CMV DNA and expression of CD38+HLA DR+ on T cells declined significantly in patients given valgancyclovir therapy <ref type="bibr" target="#b20">[21]</ref>. In parallel, autoimmune induced immune activation has also been suspected as a driver for immune activation but an association is less consistently found <ref type="bibr" target="#b21">[22]</ref>. Hence, an increase in the proportion of autoreactive T-cells has been shown by Rawson et al <ref type="bibr" target="#b22">[23]</ref>.</p><p>The contribution of each of these factors potentially varying from patient to patient and over the course of the disease is not well described. Using univariable and multivariable linear regressions, we previously evaluated the impact of cytomegalovirus-induced, microbial translocation and autoimmune-induced immune responses on chronic immune activation in 191 HIV-1-infected patients with long-term virological suppression while on antiretroviral therapy combination in the ACTHIV substudy of the ANRS CO3 Aquitaine cohort <ref type="bibr" target="#b23">[24]</ref> (S1 Table for summary results). We reported that the immune response against CMV was independently associated with a higher percentage of CD8+ T cell activation as measured by HLA-DR +/CD38+CD8+T-cells. In contrast, autoimmune response and microbial translocation were not associated with chronic immune activation in adjusted analyses. However, two difficulties limited these analyses. Firstly, each process can be measured by several biomarkers. For instance, the immune response to CMV can be measured by Quantiferon-CMV-, CMV-pp65-ELISPOT-and CMV-pp65-specific-CD8+T-cell-positivity. Therefore, each multivariable linear regression analysis considering only one marker does not reflect the whole process. Secondly, the mechanism leading to chronic immune activation is complex, multifactorial and involved intermediate pathways such as type I interferon. Autoimmunity, autoimmune diseases and the type I interferon system are closely linked. For example, a type I interferon signature can be found in many autoimmune disorders including lupus, dermatomyositis or type I diabetes. The mechanisms involved in type I interferon secretion in patients implicate the immune complexes-mediated activation of endosomal TLR activation by self DNA <ref type="bibr" target="#b24">[25,</ref><ref type="bibr" target="#b25">26]</ref>. In chronic HIV patients it has been shown that the cross-presentation of caspase-cleaved selfantigen by dendritic cells was promoting the expansion and activation of self-reactive CD8+ T cells against vimentin <ref type="bibr" target="#b22">[23]</ref>. A similar mechanism has been described in systemic lupus erythematosus patients in whom type I interferon promotes the differentiation of monocytes into dendritic cells, which are able to engulf apoptotic bodies and to present autoantigens to the adaptive immune system. Conversely, vimentin is an autoantigen targeted by the immune response in systemic lupus erythematosus patients <ref type="bibr" target="#b26">[27]</ref>. In parallel, cytomegalovirus infection may also be able to stimulate type I IFN-α production through interferon-stimulated-genes <ref type="bibr" target="#b27">[28]</ref>.</p><p>We investigated the hypotheses of direct effects of CMV-induced, autoimmune-induced immune responses measured by percentages of actin-, vimentin-, lamin-specific CD8+T-cells and microbial translocation on chronic immune activation as well as indirect effects mediated by IFN-α gene expression, in successfully treated HIV-infected patients. We aimed at unravelling the complex relationships between CMV-induced-, autoimmune-induced immune responses, microbial translocation and chronic immune activation in these patients and to explore the mediating role of the IFN-α in these processes. We carried out an entirely new work including new data from gene expression analysis which were not presented in the former study. Furthermore we realized a distinct and original approach by using an integrative structural equation modelling analysis <ref type="bibr" target="#b28">[29]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods Population</head><p>The ACTHIV study <ref type="bibr" target="#b23">[24]</ref> is a cross-sectional study nested in the ANRS CO3 Aquitaine Cohort <ref type="bibr" target="#b29">[30]</ref>, a prospective hospital-based cohort of HIV-1-infected patients, in South-Western France. Patients initiated antiretroviral therapy between 2005 and 2008, and were treated with sustained virological suppression (HIV-1 RNA load below the detection limit of 50 copies/mL) for at least two years. Exclusion criteria were two consecutive HIV-1 RNA above 50 copies/ mL, hepatitis C virus or hepatitis B virus coinfection, and signs of acute infection. The ACTHIV protocol was approved by the Bordeaux University Institutional Review Board. All patients signed an informed consent before participating in the study.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Assessments of immune responses</head><p>Available biomarkers in the ACTHIV study for assessing CMV-induced-, autoimmuneinduced immune responses, microbial translocation, quantitation of IFN-α gene expression and chronic immune activation are presented below. Methods for laboratory measurements assessed by flow cytometry have been reported in Wittkop et al <ref type="bibr" target="#b23">[24]</ref> (Material and Methods subsection entitled "Laboratory measurements").</p><p>Cytomegalovirus-induced immune response. The CMV-induced immune response was determined by CMV seropositivity and using Quantiferon CMV analysis (Cellestis, Australia), CMV-pp65 enzyme-linked immunosorbent spot (EliSpot) analysis, and HLA-A0201 CMV-pp65-specific tetramers CD8+. CMV seropositivity was assessed by detecting immunoglobulin G and immunoglobulin M antibodies to CMV late antigens (Dade Behring, Deerfield, IL). Quantiferon is a trademark of the Cellestis company, now sold by Quiagen. QuantiFER-ON-CMV uses three specific blood collection tubes that are coated with peptides simulating CD8+-specific epitopes of CMV proteins, along with negative and positive control tubes. Stimulation of CD8+ T-cells in 1 ml of whole blood with the CMV peptides induces in the production of IFN-γ in infected individuals. An ELISA is then used to measure the amount of IFN-γ present in plasma from each of the 3 tubes (Negative control, CMV antigen, and mitogen control). A robust IFN-γ response in the CMV antigen tube indicates immunity to CMV. No correction for the amount of CD4 or CD8 or ratio CD4/CD8 T-cells exists. Patients were considered Quantiferon-CMV positive if they obtained a value above 0.2 IU/mL of INFgamma, as defined by the manufacturer.</p><p>Autoimmune-induced immune response. Immune response against specific self-antigens was evaluated with anti-nuclear antibody titers (titers ! 1:250 were considered as positive) and, in HLA-A Ã 0201 positive patients, with percentages of CD8+ T-cells staining positive with actin-, vimentin-, lamin-loaded HLA-A Ã 0201 tetramers.</p><p>Microbial translocation. We measured the level of bacterial 16SrDNA as direct marker of microbial translocation together with the level of soluble CD14 (sCD14) as a surrogate marker because LPS measurements in plasma yielded hardly detectable and inconsistent values <ref type="bibr" target="#b23">[24]</ref>. Levels of sCD14 were quantified in diluted (1/50) plasma samples tested in duplicates, using an ELISA assay (Diaclone, Connecticut, USA). Plasma 16SrDNA was measured by quantitative polymerase chain reaction (PCR). Degenerate forward and reverse primers, (8F: 5'-AGAGTTTGATYMTGGCTCAG-3'; 361R: 5'-CGYCCATTGBGBAADATTCC-3'), and Taq-Man probe (338P:5'-FAM-TACGGGAGGCAGCAGT-BHQ1-3') for 16SrDNA were synthesized by Eurofins MWG biotech. A standard curve was created from serial dilutions of a plasmid DNA (pCR2.1 TOPO-16SrDNA) containing known copy numbers of the template.</p><p>Quantification of IFN-α-stimulated-genes: ADAR, ISG15, IFIT1, Mx1 and OAS1 gene expression. IFN-α gene expression was assessed using quantitative reverse transcription polymerase chain reaction (qRT-PCR) of five IFN-α-stimulated-genes: ADAR, ISG15, IFIT1, Mx1 and OAS1 <ref type="bibr" target="#b30">[31]</ref>. Total RNA was extracted from peripheral blood mononuclear cells (obtained after Ficoll preparation and storage with Protector RNAse inhibitor (Roche applied biosciences), using the High pure RNA isolation kit (Roche applied biosciences). RNA extraction quality control was measured with the Agilent 2100 bioanalyzer in combination with Agilent RNA 6000 Nano kit (RNA sample quality was considered if the obtained RIN was &gt;7). A total of 300 ng of RNA was reverse transcribed into cDNA using the Transcriptor Reverse Transcriptase kit (Roche applied biosciences). PCR was performed (RT2 SYBR Green qPCR MasterMix, SA Biosciences) in 96-wells plates using LightCycler 480 (Roche Diagnostics) to determine the expression levels of ADAR, ISG15, IFIT1, Mx1 and OAS1 target genes. IFN-α gene expression measurements were expressed as fold change which is calculated as a ratio of averages from control and test sample values.</p><p>Chronic immune T-cell activation (outcome). Activation of T cells, particularly of CD8+ T cells, is a hallmark of chronic HIV infection. Levels of CD38+ on CD8+ cells are increased in chronic HIV infection and strongly correlate with plasma viremia <ref type="bibr" target="#b31">[32]</ref>. The expression of the CD38+ is found on naive T-cells and as well on activated T-cells, whereas the expression of the HLA-DR molecule on CD8+ T cells strictly reflects the activation of T-cells. Thus, expression of activation markers including CD38 and/or HLA-DR is commonly monitored and assimilated to the degree of systemic immune activation. Of note, in patients with systemic lupus erythematosus, the expression of HLA-DR marker on CD8+ T lymphocytes correlates with disease activity <ref type="bibr" target="#b32">[33]</ref>. Our aim was to characterize autoimmune response further in chronic HIV, this is why we chose the co-expression of CD38/HLA-DR on CD8+ T cells as outcome to assess chronic immune T-cell activation. The percentage of HLA-DR+CD38+CD8+T-cells among the CD8+ T-cell subset was evaluated in blood samples by flow cytometry.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical method and model assignment</head><p>Structural equation models. Structural equation modelling with latent variables was applied to perform the integrative analysis of available biomarkers in the ACTHIV study. Structural equation models are generalizations of linear regression models, allowing for measurement error in the explanatory as well as the dependent variables. The models consist of analyses that enable direct and indirect effects between variables. The central research question often involves quantities (i.e. "latent variables"), that are unobserved variables for which no direct measurements exist. Existence of these "latent variables" may be revealed by associations among measured variables <ref type="bibr" target="#b33">[34]</ref>. Latent variables translate the fact that several observed variables could be imperfect measurements of a single underlying concept <ref type="bibr" target="#b34">[35,</ref><ref type="bibr" target="#b35">36]</ref>.</p><p>The system of structural equation models is typically decomposed into two submodels: the measurement model and the structural model <ref type="bibr" target="#b28">[29]</ref>. Firstly, the measurement model defines the construction of the latent variables with the corresponding observed measured variables (termed "indicators"), assumed to be correlated with the latent variable. In simple words, indicators are quantitative variables assumed to be normally distributed and the model for the latent variables consists of a system of linear regression models of the indicators. In this study, latent variables were built with quantitative biomarkers only. Secondly, the structural model specifies the pattern by which latent variables and observed variables influence each other, either directly or either indirectly.</p><p>Initially hypothesized model. On the basis of the background literature, we hypothesized direct effects of CMV-induced, autoimmune-induced immune responses and microbial translocation on chronic immune activation and also indirect effects (mediating role) of these factors through IFN-α gene expression. The main integrative analysis was performed in HLA-A Ã 0201 positive patients because biomarkers (tetramers), more specific than antinuclear antibody titers in chronic HIV <ref type="bibr" target="#b22">[23]</ref> to characterize autoimmune-induced immune response were available in HLA-A Ã 0201 positive patients only.</p><p>We considered four latent variables supposed to be linked with chronic immune activation:</p><p>• CMV-induced immune response latent variable measured by Quantiferon-CMV, CMV-pp65-ELISPOT and CMV-pp-65-specific-CD8+T-cells (as latent variables were built with quantitative biomarkers only, CMV seropositivity was not considered for assessing CMVinduced immune response latent variable),</p><p>• autoimmune-induced immune response latent variable measured by anti-nuclear antibody titers and percentages of CD8+ T-cells staining positive with HLA-A0201 tetramers loaded with peptides from actin-, vimentin-, lamin-autoantigens,</p><p>• microbial translocation latent variable measured by 16SrDNA and sCD14 in plasma,</p><p>• IFN-α latent variable measured by expression levels of 5 IFN-α-stimulated genes. The initial hypothesized model is presented in Fig <ref type="figure" target="#fig_0">1</ref> (hypothetical relationships between variables identified a priori).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p>Qualitative variables were described as numbers (percentages) and quantitative variables as medians (first quartile; third quartile), using SAS 9.13/SAS 9.3 (SAS Institute, Cary, NC, USA). Data preprocessing. The response variable, i.e. the percentage of HLA-DR+/CD38+ among CD8+T-cells, was log 10 transformed. IFN-α gene expression measurements were normalized to three reference genes GADPH, RPL13A, HPRT1 (housekeeping genes) using the 2 -ΔΔCT method to correct expression data for differences between samples <ref type="bibr" target="#b36">[37]</ref>.</p><p>Testing the initial model validity. The goal of structural equation modeling analysis was to determine whether our hypothesized theoretical model (Fig <ref type="figure" target="#fig_0">1</ref>), based on relevant literature, was supported by our sample data to reflect this theory. The consistency was evaluated through model-data fit, which indicated the extent to which the postulated network of relations among variables was plausible.</p><p>Structural equation models were conducted using data from subjects with no missing data for the variables included in the model (complete case analysis). Structural equation models were performed with R statistical software, using Lava package for linear latent variable models <ref type="bibr" target="#b37">[38]</ref>. Parameters were obtained by maximum likelihood estimation. We started the modeling with the initially hypothesized model (Fig <ref type="figure" target="#fig_0">1</ref>). Non-significant pathways were dropped to optimize the measurement of latent variables. The simplest and best explanation model for available data (final model) was the one maintaining the hypothesized general pathway identified from goodness-of-fit criteria. Goodness of fit was assessed using three indexes <ref type="bibr" target="#b38">[39,</ref><ref type="bibr" target="#b39">40]</ref>: the chi-square test, the Standardized Root Mean Square Residual (SRMR) and the incremental Bentler's Comparative Fit Index (CFI). Non-significant p-values at a 0.05 threshold for chisquare test, SRMR values below 0.08 and Bentler's CFI value above 0.95 indicate a good fit. Structural equation modelling results were reported as standardized estimates βstd and p-values. Standardized estimates represent the expected change in standard deviation units of a variable, due to one standard deviation increase in another. As a unit free representation, they allow comparisons of the relative strength of associations and thus easier interpretation of the coefficients.</p><p>Sensitivity analyses. We considered the use of the percentage of HLA-DR+T-cells among CD8+ blood T-lymphocytes as the outcome to define chronic immune activation in the HLA-A Ã 0201 positive sample. In addition an analysis in the overall sample was performed considering the CMV-induced immune response measured by Quantiferon-CMV (positive, i.e. ! 0.2 IU/mL vs. negative, i.e. &lt; to 0.2 IU/mL) and the autoimmune-induced immune response measured by anti-nuclear antibody titers (positive, i.e. ! 1:250 vs. negative, i.e. &lt; 1:250).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients' characteristics</head><p>A total of 191 patients were enrolled in the ACTHIV study (women: 25%). Median age at inclusion was 50 years old <ref type="bibr">(43; 58)</ref>. Median duration of viral suppression was 6.1 years (4; 8.5). Median CD4+ and CD8+ T-cell counts were 517 cells/μL (387; 720) and 676 cells/μL (480; 977). Patients had a median CD4+ nadir of 188 cells/μL (89; 275).</p><p>Of the 191 patients, 87 were HLA-A Ã 0201 positive patients. There were no differences between HLA-A2 patients and the overall population except for the availability of measurements of percentages of CMV-pp65-specific tetramers CD8+ and actin-, vimentin-, lamin-specific CD8+T-cells in the HLA-A Ã 0201 population (restricted tests).</p><p>Demographic, clinical and biological characteristics of the 87 HLA-A Ã 0201 positive patients were representative of the overall population of 191 patients (Table <ref type="table" target="#tab_1">1A</ref> and<ref type="table" target="#tab_1">1B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Measurement of the processes</head><p>Main patient's characteristics of variables related to CMV-, autoimmune-induced immune responses and microbial translocation are reported in Table <ref type="table" target="#tab_1">1B</ref>. In the overall population, Quantiferon-CMV was positive in 78% of patients and antinuclear antibodies were positive in 26% of patients. In the HLA-A Ã 0201 positive patients, Quantiferon-CMV was positive in 82% and antinuclear antibodies were positive in 28% of patients. Levels of the tested self-antigenspecific T cells were low in this study. Levels of 16SrDNA and sCD14 for studying microbial translocation did not differ between the HLA-A Ã 0201 positive patients and the overall population (Table <ref type="table" target="#tab_1">1B</ref>). Of the 87 HLA-A Ã 0201 positive patients, the main complete analysis was performed in the 57 patients in whom the percentages of actin-, vimentin-, lamin-specific CD8+T-cells as well as Quantiferon, pp-65 ELISPOT for CMV were available (subjects with missing values for variables included in the model were excluded). The 30 other patients did not differ from the 57 HLA-A Ã 0201 positive patients included in the final analysis. In the 57 patients, median % of HLA-DR+/CD38+CD8+T-cells was 15.8 (11.7; 23.2). Median % actin-specific-CD8+ T cells, % vimentin-specific-CD8+ T cells, % lamin-specific-CD8+ T cells were respectively 0.03 (0.02; 0.06), 0.01 (0.01; 0.02) and 0.01 (0.01; 0.02). Median Quantiferon-CMV values were 5.3 IU/mL (0.4; 11.5) and median CMV-pp65-ELISPOT values were 309 (95; 645). IFN-α gene expression measurements were positively and significantly correlated with the percentages of HLA-DR +/CD38+CD8+T-cells (Fig <ref type="figure" target="#fig_1">2)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Main integrative analysis in HLA-A*0201 positive patients</head><p>Model building. The model building started with the model represented in Fig 1 . As biomarkers of microbial translocation were not associated with chronic immune activation in univariable analysis (16SrDNA effect: p-value = 0.6100; sCD4 effect: p-value = 0.9750; microbial translocation latent variable: p-value = 0.9922) and in multivariable analysis performed in our previous work <ref type="bibr" target="#b23">[24]</ref>, they were dropped from the final model. Anti-nuclear antibodies were not contributive for the definition of the autoimmune-induced immune response latent variable (p-value = 0.2785) as well as CMV-pp65-specific-CD8+ T-cells for the definition of the CMV-induced immune response latent variable (p-value = 0.7049). Therefore, further analyses included the effect of CMV-induced immune response measured by Quantiferon and pp-65 ELISPOT, autoimmune-induced immune response measured by actin, vimentin, lamin-specific CD8+, interferon-α pathway measured by the expression level of the five interferon signaling genes (ADAR, ISG15, IFIT1, Mx1 and OAS1) and chronic immune activation.</p><p>Final model. The final best-fit model for ACTHIV data is shown in Fig <ref type="figure" target="#fig_2">3</ref> ant the corresponding results are presented in Table <ref type="table">2</ref>.</p><p>Quantiferon-CMV (βstd = 0.61) and CMV-pp-65-ELISPOT (βstd = 0.51) contributed significantly to the CMV-induced response. The positive significant standardized estimates mean that higher levels of CMV-induced response were associated with higher levels of Quantiferon-CMV and CMV-pp-65-ELISPOT. Autoimmune-induced response was composed by % actin-specific-CD8+ T cells, % vimentin-specific-CD8+ T cells and % lamin-specific-CD8+ T cells. All standardized estimates were positive. The percentage of vimentin-specific-CD8+ T cells presented the highest contribution to explain the autoimmune-induced response variation (βstd = 0.52, p-value = 0.0006). IFN-α gene latent variable was composed of expression levels of IFN-α-stimulated genes: ADAR (βstd = 0.59), ISG15 (βstd = 0.54), IFIT1 (βstd = 0.94), Mx1 (βstd = 0.93), OAS1 (βstd = 0.77).</p><p>The analysis of the effect of each single process revealed a direct association of chronic immune activation of CD8+ T-cells with CMV-induced response (βstd = 0.42, p-value = 0.0232), and with IFN-α genes (βstd = 0.31, p-value = 0.0093). No direct effect of autoimmune-induced response and chronic immune activation was found (βstd = 0.04, p-value = 0.7361). However, autoimmune-induced response was associated with IFN-α genes (βstd = 0.33, p-value = 0.0457).</p><p>The structural model including all processes presented in Fig <ref type="figure" target="#fig_2">3 revealed</ref> a direct positive significant effect of the CMV-induced response on chronic immune activation (βstd = 0.56, p-value = 0.0004) but no significant association with the IFN-α genes (p-value = 0.9069). There was no direct significant association of autoimmune-induced response and chronic immune activation (p-value = 0.3169). The effect of autoimmune-induced response on chronic immune activation was indirect through IFN-α genes: autoimmune-induced response was significantly associated with IFN-α genes (βstd = 0.36, p-value = 0.0401) and IFN-α genes were associated with chronic immune activation (βstd = 0.39, p-value = 0.0044). The goodness  ).</p><p>When defining CD8+ T-cell activation with % CD8+HLA-DR+ T cells (log 10 transformed) in place of % CD8+CD38+HLA-DR+ as the outcome, the adjusted results were consistent (S3 Table ). There was a direct positive significant effect of CMV-induced response on chronic immune activation (βstd = 0.45, p-value = 0.0056) as well as an indirect effect of autoimmuneinduced response on chronic immune activation through IFN-α genes. Autoimmune-induced response was significantly associated with IFN-α genes (βstd = 0.35, p-value = 0.0345) and IFN-α genes were associated with chronic immune activation (βstd = 0.35, p-value = 0.0111).</p><p>Sensitivity analysis in the overall population. Of the 191 patients included in the ACTHIV study, the sensitivity analysis was performed in 142 patients in whom Quantiferon-CMV positive versus negative, anti-nuclear antibody titers positive versus negative, interferonstimulated genes and % HLA-DR+/CD38+CD8+ T-cells were available (including the 57 patients from the main integrative analysis). In these patients, median % of HLA-DR+/CD38 +CD8+T-cells was 16.9 (10.8; 23.7), Quantiferon-CMV was positive in 78% of patients and antinuclear antibodies were positive in 23% of patients. The adjusted results were roughly consistent with previous results (S4 Table ). Quantiferon-CMV positivity was associated with higher percentage of CD8+CD38+HLA-DR+ (βstd = 0.15, p-value = 0.0648), positive antinuclear antibody titers were associated with higher expression of IFN-α genes (βstd = 0.16, pvalue = 0.0797) and higher IFN-α-gene expression was associated with chronic immune activation (βstd = 0.22, p-value = 0.0120). </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>Exploring the mechanisms driving chronic immune activation in successfully treated HIVinfected patients requires a statistical modelling approach. Testable pathways need to be identified a priori and hypotheses regarding the relationships between multifactorial triggers involved in chronic HIV need to be challenged by this approach. Common strategies for multiple markers are to analyze each marker separately or to include original markers simultaneously as predictors in multivariable regression models, assuming the presence of one single relationship between variables. In addition to neglecting any a priori knowledge, these strategies could lead to invalidate results due to: i) type I error inflation from multiple testings, ii) type II errors (missing true associations) because immune markers only reflect a small part of the variation of the underlying immunological mechanism, iii) estimation problems due to multicollinearity or neglected measurement errors. Thus, to unravel the complexity of research questions addressed by modern immunological studies, sophisticated statistical approaches are necessary <ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref>.</p><p>In this study, we considered the potential for using SEM to investigate the mediating role of INF-α in chronic immune activation in successfully treated HIV-infected patients. The advantage of SEM is to use all available information in an integrative analysis, avoiding the methodological issues mentioned above. Moreover, latent variables are defined by several markers that could reflect an underlying immunological mechanism and SEM considers a priori knowledge limiting the number of analyses to run and multiple testing. Due to availability of percentages of actin-, vimentin-, lamin-specific CD8+T-cells (HLA-A2-restricted tests) to further characterize autoimmune response, we performed our main analysis in a subsample of HLA-A2 patients making the whole study original compared to the previously published <ref type="bibr" target="#b23">[24]</ref>. The mediating role of INF-α has been investigated and underlying activation processes were defined as latent variables, i.e. CMV-induced-, autoimmune-induced immune responses, microbial translocation and INF-α. The best explanation model for the available data was identified from goodness-of-fit-criteria. SEM final results revealed a direct positive significant effect of CMV-induced response and IFN-α genes on chronic immune activation. In addition, the approach might suggest an indirect effect of autoimmune-induced response on chronic immune activation through IFN-α genes. These findings were consistent in various sensitivity analyses performed in HLA-A Ã 0201 positive patients and in the overall population. Results in the overall population could be explained by the fact that Quantiferon-CMV positivity and positivity of anti-nuclear antibody titers may not be accurate enough for reflecting respectively the CMV-induced response and the autoimmune-induced response leading to a dilution bias and underlying the need for an integrative analysis using all available information.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Table 2. Effects of cytomegalovirus-, autoimmune-induced immune responses on chronic immune activation (HLA-DR+/CD38+CD8+ T-cells log10%), HLA-A*0201 positive patients (n = 57). Main integrative analysis to read in conjunction with</head><p>Particularly, all analyses highlighted the significant effect of IFN-α genes on chronic immune activation, accounting for the evidence of the involvement of the IFN-α pathway reported in chronic immune activation in successfully treated HIV-1-infected patients <ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref>.</p><p>We confirmed effect of the CMV-induced response on chronic immune activation <ref type="bibr" target="#b23">[24]</ref>. Our findings are in agreement with former studies highlighting the involvement of CMV in immunosenescence and chronic HIV infection <ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b48">[49]</ref>. According to this new analysis, the effect of CMV-induced response on CD8+ T-cell activation was not mediated by the IFN-αgenes measured in the present study (ADAR, ISG15, IFIT1, Mx1 and OAS1). The direct effect of CMV-induced response on chronic immune activation was revealed through the measurements of Quantiferon and pp-65 ELISPOT. CMV-tetramer-pp65-specific-CD8+ T-cells were not contributive to define the CMV-induced immune response latent variable (p = 0.7049). Stone et al <ref type="bibr" target="#b49">[50]</ref> reported that percentages of CMV-pp65-specific-CD8+ T-cells were similar in HIV patients with stable undetectable HIV viremia due to highly active antiretroviral therapy and healthy controls. Taking together, these findings indicate that CMV-pp65-specific-CD8+ T-cells in circulating blood may not reflect accurately the status of the response against CMV and thus, question the relevance of measuring them at distance of the primo-infection or of reactivations in blood. Indeed, anti-CMV response may primarily rely on in situ tissue resident memory T-cells <ref type="bibr" target="#b50">[51]</ref> which do not recirculate in blood but rather stay in barrier tissue such as lung, skin or intestine. Therefore the lack of correlation between tetramer positive T-cells and CMV does not mean they do not exist but that they are not circulating in the blood we were looking at.</p><p>Interestingly, our results might suggest an indirect effect of autoimmune-induced response on chronic immune activation mediated through IFN-α genes. Even in the absence of clinical events, low level biological signals may have consequences such as T-cell activation. The effect of autoimmune-induced immune response on IFN-α latent variable was revealed through the measurements of actin-, vimentin-, lamin-specific CD8+T-cells illustrating the important role of caspase-cleaved apoptotic self-antigens in immune activation during chronic HIV infection, as suggested by Rawson et al <ref type="bibr" target="#b22">[23]</ref>. Of note, the percentage of vimentin-specific CD8+T-cells contributed the most to define the autoimmune-induced response latent variable. Moreover, the use of a latent variable seemed particularly relevant regarding the low levels of self-antigenspecific T cells in this study. Indeed, anti-nuclear antibodies did not contribute to the definition of the autoimmune-induced response latent variable and were dropped from the final model. The latter result reveals the need to measure biomarkers more relevant than antinuclear antibodies when studying autoimmune-induced response in chronic HIV <ref type="bibr" target="#b22">[23]</ref>. Altogether, these findings might provide valuable insights in hypotheses regarding the role of autoimmunity, as there were very few reports in the literature studying auto-immunity in HIV infected patients <ref type="bibr" target="#b21">[22]</ref>. However, these findings need to be interpreted carefully because i) there was no direct significant association of autoimmune-induced response with chronic immune activation, ii) even though the use of a latent variable seemed particularly relevant for defining the autoimmune-induced immune response, the very low levels of self-antigen-specific T cells in this study may raise concerns about the existence of a biological autoimmunity affecting immune activation sufficiently.</p><p>Previous studies have demonstrated that bacterial translocation (measured by sCD14 and 16SrDNA) was associated with immune activation. In this work, biomarkers of microbial translocation were not associated with chronic immune activation in univariable analysis and in multivariable analysis performed in our previous work <ref type="bibr" target="#b23">[24]</ref>. This could be explained by the very specific characteristics of our population: median duration of viral suppression 5.8 years (IQR: 4.4; 7.7), median duration of ART exposure 10.5 years (5.9; 13.4), with very low levels of microbial translocation: median sCD14 μg/mL 1.8 (1.6; 1.9), median 16S rDNA log10 copies/ mL 3.3 (3.1; 3.4) (data for HLA-A2 patients). Moreover, Abad-Fernandez M et al did not find any correlation between sCD14 or bacterial rDNA with activated CD8 T cells in long-term suppressed HIV-1-infected individuals <ref type="bibr" target="#b51">[52]</ref>.</p><p>Our study also had some limitations. First, the ACTHIV study is a cross-sectional study nested in the ANRS CO3 Aquitaine Cohort not allowing to infer the temporality and causal direction of the observed associations. Enrolled patients initiated antiretroviral therapy between 2005 and 2008 and were virologically suppressed for at least two years. Median duration of viral suppression was 6.1 years (4; 8.5) in the overall population and 5.8 years (4.4; 7.7) in the HLA-A2 population. We had no other data on persistent ongoing HIV replication. This is a clear limitation of the study. Second, even though our results were confirmed in all sensitivity analyses, the main complete case integrative analysis was performed in 66% (57/87) HLA-A Ã 0201 positive patients, accounting for a potential lack of power that may have affected results on the effects of autoimmunity and SEM model identifiability (generally the greater the model complexity, the more observations are needed), questioning the need for additional methods such as multiple imputation. Third, we had only five quantitative gene expression measurements of IFN-α-stimulated-genes. Some studies report more specific pathways of IFN-α that could be involved in HIV chronic immune activation, i.e. IFN-α MYD88 dependent pathway and IFN-α MYD88 independent pathway <ref type="bibr" target="#b52">[53]</ref><ref type="bibr" target="#b53">[54]</ref><ref type="bibr" target="#b54">[55]</ref>. Additional data on these pathways may have helped to better characterize the potential indirect effects of CMV or microbial translocation on chronic immune activation. Further research is needed and could be implemented in a longitudinal framework, allowing the inference of causal relationships. Combining appropriate biomarkers and adequate quantitative gene expression measurements, including IFN-α, using structural equation modelling could also be applied in longitudinal data analysis <ref type="bibr" target="#b55">[56]</ref>. Indeed, ongoing efforts are made to identify and better characterize the IFN-α-stimulated-genes landscape <ref type="bibr" target="#b56">[57,</ref><ref type="bibr" target="#b57">58]</ref>.</p><p>We focused on chronic immune T-cell activation, proven to be a leading factor for HIV disease progression but we acknowledge the importance of other markers including B cells, Natural Killer cells, dendritic cells, monocytes, macrophages and neutrophils of the inflammation cascade, as well as of the endothelium and the coagulation system in immune activation <ref type="bibr" target="#b58">[59]</ref>. We do feel that this study additionally illustrates the potential of latent variables, in modern immunology, to assess biological processes that cannot be measured directly.</p><p>In this study, we used structural equation modeling analysis to determine whether our hypothesized theoretical model (Fig <ref type="figure" target="#fig_0">1</ref>) was supported by sample data to reflect our theory in chronic HIV. The simplest and best explanation model for available data maintaining the hypothesized general pathway (Fig <ref type="figure" target="#fig_2">3</ref>) passed the goodness-of-fit tests. As estimation techniques, modeling capacities and breadth of SEM applications are expanding rapidly, beyond social sciences, to embrace multiple fields as modern immunology <ref type="bibr" target="#b40">[41,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44]</ref>, endocrinology <ref type="bibr" target="#b59">[60]</ref>, cancer <ref type="bibr" target="#b60">[61,</ref><ref type="bibr" target="#b61">62]</ref> or environment <ref type="bibr" target="#b62">[63]</ref>, we would like to warn readers about SEM results that have to be interpreted carefully. Indeed, because a model fits the data well does not mean that the model reflects perfectly the reality. Other statistical plausible models could have fitted the data <ref type="bibr" target="#b28">[29]</ref> but the advantage of SEM is to consider prior knowledge limiting the number of analyses to run and multiple testing. This is why, beyond the need to report a detailed statistical justification of the model (specification, identifiability, estimation, goodness of fit) <ref type="bibr" target="#b28">[29]</ref>, we highlight the importance to integrate the expertise of specialists in the field when defining the testable pathways and when designing the initial hypothesized theoretical model. Particularly, carefully conducted SEM analyses with a minimal number of weak assumptions provide an important supplement to standard regression results (i.e. mediation, measurement error in explanatory variables). In conclusion, this study not only provides valuable insights into underlying mechanisms of chronic immune activation in HIV-infection but also illustrates the potential of SEM for handling multiple relationships, understanding epidemiological processes using observational data. Furthermore, the results clearly highlight the need for integrative analyses to make the most out of immunological data <ref type="bibr" target="#b63">[64,</ref><ref type="bibr" target="#b64">65]</ref>. Using this flexible framework, the role of CMV-immune response on the CD8+ T cell activation has been confirmed, encouraging intervention against CMV in successfully treated HIV-1-infected patients <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b65">66]</ref>. Our results further add to the growing body of evidence that IFN-α is involved in chronic immune activation. The signal found for the potential role of auto-immunity response in chronic immune activation requires further investigations.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig 1 .</head><label>1</label><figDesc>Fig 1. Initially hypothesized model representing the effects of cytomegalovirus-induced, autoimmune-induced immune responses and microbial translocation on chronic immune activation (model adjusted on age, CD4+ T-cell count and regulatory T-cell count). ACTHIV study. Boxes: observed variables; ellipses: latent variables; ε: measurement errors. doi:10.1371/journal.pone.0169164.g001</figDesc><graphic coords="6,59.98,369.07,515.91,302.57" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig 2 .</head><label>2</label><figDesc>Fig 2. Spearman correlations between percentages of CD8+CD38+HLA-DR+ T-cells and IFN-α gene expression measurements, HLA-A*0201 positive patients (n = 57). ACTHIV study. A) ADAR: r = 0.31, p-value = 0.0180; B) ISG15: r = 0.34, p-value = 0.0085; C) IFIT1: r = 0.32, p-value = 0.0166; D) Mx1: r = 0.29, p-value = 0.0301; E) OAS1: r = 0.35, p-value = 0.0077. doi:10.1371/journal.pone.0169164.g002</figDesc><graphic coords="10,59.98,78.01,515.91,360.40" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig 3 .</head><label>3</label><figDesc>Fig 3. Final hypothesized model representing the effects of cytomegalovirus-induced-, autoimmune-induced immune responses latent variables on chronic immune activation. Figure to read in conjunction with Table 2. ACTHIV study. Boxes: observed variables; ellipses: latent variables; measurement errors deleted for clarity.*p-values &lt; 0.05. **p-values &lt; 0.0001. doi:10.1371/journal.pone.0169164.g003</figDesc><graphic coords="11,59.98,73.13,515.91,285.73" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 . Demographic, clinical and biological patients' characteristics.</head><label>1</label><figDesc>ACTHIV study.</figDesc><table><row><cell>A</cell></row><row><cell>Characteristics</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc>(Continued)    </figDesc><table><row><cell>A</cell></row><row><cell>Characteristics</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>βstd* p value Measurement models (latent variable definitions) Cytomegalovirus(CMV)-induced immune response latent variable</head><label></label><figDesc>Fig 3. ACTHIV study.</figDesc><table><row><cell>Process</cell><cell></cell><cell></cell></row><row><cell>CMV response latent variable ! Quantiferon-CMV</cell><cell>0.61</cell><cell>&lt; 0.0001</cell></row><row><cell>CMV response latent variable ! CMV-pp-65-ELISPOT</cell><cell>0.51</cell><cell>&lt; 0.0001</cell></row><row><cell>Autoimmune(AI)-induced immune response latent variable</cell><cell></cell><cell></cell></row><row><cell>AI response latent variable ! % actin-specific-CD8+</cell><cell>0.23</cell><cell>0.0862</cell></row><row><cell>AI response latent variable ! % vimentin-specific-CD8+</cell><cell>0.52</cell><cell>0.0006</cell></row><row><cell>AI response latent variable ! % lamin-specific-CD8+</cell><cell>0.39</cell><cell>0.0184</cell></row><row><cell>IFN-α-stimulated-genes latent variable</cell><cell></cell><cell></cell></row><row><cell>IFN-α-stimulated-genes latent variable ! ADAR</cell><cell>0.59</cell><cell>&lt; 0.0001</cell></row><row><cell>IFN-α-stimulated-genes latent variable ! ISG15</cell><cell>0.54</cell><cell>&lt; 0.0001</cell></row><row><cell>IFN-α-stimulated-genes latent variable ! IFIT1</cell><cell>0.94</cell><cell>&lt; 0.0001</cell></row><row><cell>IFN-α-stimulated-genes latent variable ! Mx1</cell><cell>0.93</cell><cell>&lt; 0.0001</cell></row><row><cell>IFN-α-stimulated-genes latent variable ! OAS1</cell><cell>0.77</cell><cell>&lt; 0.0001</cell></row><row><cell>Structural model</cell><cell></cell><cell></cell></row><row><cell>CMV response latent variable ! IFN-α-stimulated-genes latent variable</cell><cell>0.02</cell><cell>0.9069</cell></row><row><cell>CMV response latent variable ! % HLA-DR+/CD38+CD8+</cell><cell>0.56</cell><cell>0.0004</cell></row><row><cell>AI response latent variable ! IFN-α-stimulated-genes latent variable</cell><cell>0.36</cell><cell>0.0401</cell></row><row><cell>AI response latent variable ! % HLA-DR+/CD38+CD8+</cell><cell>-0.10</cell><cell>0.3169</cell></row><row><cell>IFN-α-stimulated-genes latent variable ! % HLA-DR+/CD38+CD8+</cell><cell>0.39</cell><cell>0.0044</cell></row><row><cell>* Standardized estimates</cell><cell></cell><cell></cell></row><row><cell>doi:10.1371/journal.pone.0169164.t002</cell><cell></cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>PLOS ONE | DOI:10.1371/journal.pone.0169164 January 3, 2017</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>We thank all patients for their participation. We thank the technicians from the immunologic routine laboratory of the <rs type="affiliation">CHU Bordeaux</rs> for excellent technical assistance.</p></div>
			</div>
			<div type="funding">
<div><p>This work was supported by <rs type="funder">Sidaction</rs> [<rs type="grantNumber">AI20-2-01629</rs>], the <rs type="funder">CHU of Bordeaux</rs> [<rs type="grantNumber">2009 AO1063-54</rs>] and the <rs type="institution">Vaccine Research Institute</rs>. The <rs type="funder">ANRS</rs> <rs type="grantNumber">CO3</rs> Aquitaine cohort was supported by the <rs type="funder">Agence nationale de recherches sur le sida et les he ´patites virales [ANRS</rs>, <rs type="funder">Action</rs> Coordonne ´e no.7, Cohortes].</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_K95Yvp6">
					<idno type="grant-number">AI20-2-01629</idno>
				</org>
				<org type="funding" xml:id="_guAkcAM">
					<idno type="grant-number">2009 AO1063-54</idno>
				</org>
				<org type="funding" xml:id="_Y66brWp">
					<idno type="grant-number">CO3</idno>
				</org>
			</listOrg>

			<div type="availability">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>All relevant data are within the paper and its Supporting Information files.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supporting Information</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S1 Table. Univariable and multivariable linear regressions of HLA-DR+/CD38+CD8+ Tcells (log10%). ACTHIV study. (DOC)</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>S2 Table. Effects of cytomegalovirus-, autoimmune-induced immune responses on chronic immune activation (HLA-DR+/CD38+CD8+ T-cells log10%), adjusted for age, CD4+ Tcell count and regulatory T-cell count. HLA-A</head></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Kitchen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gascon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Narvaez</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2003-09-3333</idno>
		<idno type="PMID">15117761</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="942" to="947" />
			<date type="published" when="2004-08-15">2004 Aug 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Immune activation and AIDS pathogenesis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Sodora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Silvestri</surname></persName>
		</author>
		<idno type="DOI">10.1097/QAD.0b013e3282f2dbe7</idno>
		<idno type="PMID">18301056</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="439" to="446" />
			<date type="published" when="2008-02-19">2008 Feb 19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Immunologic basis of cardiovascular disease in HIV-infected adults</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Hsue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hunt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<date type="published" when="0205">2012 Jun; 205</date>
		</imprint>
	</monogr>
	<note>Suppl 3:S375-82</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Plaeger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Musib</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Deeks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Read</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Embry</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">AIDS Res Hum Retroviruses</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="469" to="477" />
			<date type="published" when="2012-05">May 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tebas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Henry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Matining</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Weng-Cherng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Valdez</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0002021</idno>
		<idno type="PMID">18431498</idno>
	</analytic>
	<monogr>
		<title level="j">PloS One</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">2021</biblScope>
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Aging and inflammation in patients with HIV infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Biasi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gibellini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bianchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pecorini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bacca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Immunol</title>
		<imprint>
			<date type="published" when="2016-05-20">2016 May 20</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Persistent LCMV infection is controlled by blockade of type I interferon signaling</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Teijaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Sheehan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Welch</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1235214</idno>
		<idno type="PMID">23580529</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="issue">6129</biblScope>
			<biblScope unit="page" from="207" to="211" />
			<date type="published" when="2013-04-12">2013 Apr 12</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Blockade of chronic type I interferon signaling to control persistent LCMV infection</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Elsaesser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Herskovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Deng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cheng</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1235208</idno>
		<idno type="PMID">23580528</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">340</biblScope>
			<biblScope unit="issue">6129</biblScope>
			<biblScope unit="page" from="202" to="207" />
			<date type="published" when="2013-04-12">2013 Apr 12</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Moorman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">Q</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">S</forename><surname>Jia</surname></persName>
		</author>
		<idno type="DOI">10.1111/imm.12349</idno>
		<idno type="PMID">24965611</idno>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="319" to="330" />
			<date type="published" when="2014-11">2014 Nov</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Type I IFN-a blunt spear in fighting HIV-1 infection</title>
		<author>
			<persName><forename type="first">C</forename><surname>Acchioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Marsili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Perrotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Remoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sgarbanti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Battistini</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cytogfr.2014.10.004</idno>
		<idno type="PMID">25466629</idno>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="143" to="158" />
			<date type="published" when="2015-04">2015 Apr</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Interferon-alpha, immune activation and immune dysfunction in treated HIV infection</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Berry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nolan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>French</surname></persName>
		</author>
		<idno type="DOI">10.1038/cti.2014.1</idno>
		<idno type="PMID">25505958</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Transl Immunology</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">10</biblScope>
			<date type="published" when="2014-02-28">2014 Feb 28</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Pritschet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schmidt</surname></persName>
		</author>
		<idno type="DOI">10.1155/2012/534929</idno>
		<idno type="PMID">22203858</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Dev Immunol</title>
		<imprint>
			<biblScope unit="volume">2012</biblScope>
			<biblScope unit="page">534929</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Persistent immune activation in chronic HIV infection: do any interventions work?</title>
		<author>
			<persName><forename type="first">R</forename><surname>Rajasuriar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Khoury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kamarulzaman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">U</forename><surname>Cameron</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Lewin</surname></persName>
		</author>
		<idno type="DOI">10.1097/QAD.0b013e32835ecb8b</idno>
		<idno type="PMID">23324661</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1199" to="1208" />
			<date type="published" when="2013-05-15">2013 May 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Immune activation and inflammation in HIV-1 infection: causes and consequences</title>
		<author>
			<persName><forename type="first">V</forename><surname>Appay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sauce</surname></persName>
		</author>
		<idno type="DOI">10.1002/path.2276</idno>
		<idno type="PMID">18161758</idno>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="231" to="241" />
			<date type="published" when="2008-01">2008 Jan</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Microbial translocation is a cause of systemic immune activation in chronic HIV infection</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brenchley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Schacker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Asher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Silvestri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rao</surname></persName>
		</author>
		<idno type="DOI">10.1038/nm1511</idno>
		<idno type="PMID">17115046</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1365" to="1371" />
			<date type="published" when="2006">2006Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Microbial translocation, immune activation, and HIV disease</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Klatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Funderburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Brenchley</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.tim.2012.09.001</idno>
		<idno type="PMID">23062765</idno>
	</analytic>
	<monogr>
		<title level="j">Trends Microbiol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="6" to="13" />
			<date type="published" when="2013-01">2013 Jan</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Plasma Levels of Bacterial DNA Correlate with Immune Activation and the Magnitude of Immune Restoration in Persons with Antiretroviral-Treated HIV Infection</title>
		<author>
			<persName><forename type="first">W</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lederman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Sieg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Haley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Rodriguez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1177" to="1185" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Old age and anticytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients</title>
		<author>
			<persName><forename type="first">V</forename><surname>Appay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fastenackels</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Katlama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ait-Mohand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guihot</surname></persName>
		</author>
		<idno type="DOI">10.1097/QAD.0b013e32834640e6</idno>
		<idno type="PMID">21412126</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="1813" to="1822" />
			<date type="published" when="2011-09-24">2011 Sep 24</date>
		</imprint>
	</monogr>
	<note>b013e32834640e6</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Hsue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sinclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bredt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Franklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Killian</surname></persName>
		</author>
		<idno type="DOI">10.1097/QAD.0b013e3280108704</idno>
		<idno type="PMID">17117013</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="2275" to="2283" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Parrinello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sinclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Landay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lurain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Sharrett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Gange</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jis276</idno>
		<idno type="PMID">22492856</idno>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">205</biblScope>
			<biblScope unit="page" from="1788" to="1796" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Hunt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sinclair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Epling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Teague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Jacobson</surname></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jir060</idno>
		<idno type="PMID">21502083</idno>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">203</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1474" to="1483" />
			<date type="published" when="2011-05-15">2011 May 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">R</forename><surname>Stratton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Slapak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mahungu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kinloch-De Loes</surname></persName>
		</author>
		<author>
			<persName><surname>Autoimmunity</surname></persName>
		</author>
		<author>
			<persName><surname>Hiv</surname></persName>
		</author>
		<idno type="DOI">10.1097/QCO.0b013e3283210006</idno>
		<idno type="PMID">19532080</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="49" to="56" />
			<date type="published" when="2009-02">2009 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Rawson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Molette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Videtta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Altieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Franceschini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Donato</surname></persName>
		</author>
		<idno type="DOI">10.1038/nm1679</idno>
		<idno type="PMID">18026114</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1431" to="1439" />
			<date type="published" when="2007-12">2007 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort</title>
		<author>
			<persName><forename type="first">L</forename><surname>Wittkop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bitard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lazaro</forename><forename type="middle">E</forename><surname>Neau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mercie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jis732</idno>
		<idno type="PMID">23204178</idno>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">622</biblScope>
			<date type="published" when="2013-02-15">2013 Feb 15</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Type I interferon in systemic lupus erythematosus and other autoimmune diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Banchereau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pascual</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.immuni.2006.08.010</idno>
		<idno type="PMID">16979570</idno>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="383" to="392" />
			<date type="published" when="2006-09">2006 Sep</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Dendritic cells and cytokines in human inflammatory and autoimmune diseases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Palucka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pascual</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Banchereau</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cytogfr.2007.10.004</idno>
		<idno type="PMID">18258476</idno>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="41" to="52" />
			<date type="published" when="2008-02">2008 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Vimentin is a dominant target of in situ humoral immunity in human lupus tubulointerstitial nephritis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kinloch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Henry</forename><surname>Dunand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Maienschein-Cline</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1002/art.38888</idno>
		<idno type="PMID">25306868</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheumatol</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3359" to="3370" />
			<date type="published" when="2014-12">2014 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Characterization of the elements and proteins responsible for interferon-stimulated gene induction by human cytomegalovirus</title>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Netterwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhu</surname></persName>
		</author>
		<idno type="DOI">10.1128/JVI.79.8.5027-5034.2005</idno>
		<idno type="PMID">15795288</idno>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="5027" to="5034" />
			<date type="published" when="2005-04">2005 Apr</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Structural Equation Models: A Review With Applications to Environmental Epidemiology</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Sanchez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Budtz-Jorgensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Ryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JASA</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">472</biblScope>
			<biblScope unit="page" from="1443" to="1455" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d&apos;Epidemiologie du SIDA en Aquitaine (GECSA)</title>
		<author>
			<persName><forename type="first">R</forename><surname>Thiebaut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Morlat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jacqmin-Gadda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Neau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mercie</forename><forename type="middle">P</forename><surname>Dabis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
		<idno type="PMID">10853978</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="971" to="978" />
			<date type="published" when="2000-05-26">2000 May 26</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Regulation of type I interferon responses</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Ivashkiv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Donlin</surname></persName>
		</author>
		<idno type="DOI">10.1038/nri3581</idno>
		<idno type="PMID">24362405</idno>
	</analytic>
	<monogr>
		<title level="j">Nature reviews Immunology</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="36" to="49" />
			<date type="published" when="2014-01">2014 Jan</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">CD38 expression on CD8 T lymphocytes as a marker of residual virus replication in chronically HIV-infected patients receiving antiretroviral therapy</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Benito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lo ´pez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gonza ´lez-Lahoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Soriano</surname></persName>
		</author>
		<idno type="DOI">10.1089/088922204773004950</idno>
		<idno type="PMID">15018711</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS Res Hum Retroviruses</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="227" to="233" />
			<date type="published" when="2004-02">2004 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus</title>
		<author>
			<persName><forename type="first">P</forename><surname>Blanco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pitard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Viallard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Taupin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pellegrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Moreau</surname></persName>
		</author>
		<idno type="DOI">10.1002/art.20745</idno>
		<idno type="PMID">15641052</idno>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="page" from="201" to="211" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Guidelines for a graph-theoretic implementation of structural equation modeling</title>
		<author>
			<persName><forename type="first">J B</forename><surname>Grace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Schoolmaster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Guntenspergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Little</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Mitchell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ecosphere</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">73</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Latent variables and structural equation models for longitudinal relationships: an illustration in nutritional epidemiology</title>
		<author>
			<persName><forename type="first">M</forename><surname>Chavance</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Escolano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Basdevant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>De Lauzon-Guillain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Charles</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2288-10-37</idno>
		<idno type="PMID">20433707</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Med Res Methodol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">37</biblScope>
			<date type="published" when="2010-04-30">2010 Apr 30</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">A structural equation model of the developmental origins of blood pressure</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Dahly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Adair</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Bollen</surname></persName>
		</author>
		<idno type="DOI">10.1093/ije/dyn242</idno>
		<idno type="PMID">19039006</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="538" to="548" />
			<date type="published" when="2009-04">2009 Apr</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Livak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Schmittgen</surname></persName>
		</author>
		<idno type="DOI">10.1006/meth.2001.1262</idno>
		<idno type="PMID">11846609</idno>
	</analytic>
	<monogr>
		<title level="j">Methods</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="402" to="408" />
			<date type="published" when="2001-12">2001 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Linear latent variable models: the lava-package</title>
		<author>
			<persName><forename type="first">Kk J E</forename><surname>Holst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comput Stat</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1385" to="1452" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<monogr>
		<title level="m" type="main">Handbook of Structural Equation Modeling</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Hoyle</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2012">2012</date>
			<publisher>Guildford Press</publisher>
			<pubPlace>New York</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Cutoff criteria for fit indexes in covariance structure analysis: conventional criteria versus new alternatives</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Bentler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Structural Equation Modeling</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="55" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">A guide to modern statistical analysis of immunological data</title>
		<author>
			<persName><forename type="first">B</forename><surname>Genser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yazdanbakhsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Barreto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Rodrigues</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2172-8-27</idno>
		<idno type="PMID">17963513</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Immunol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">27</biblScope>
			<date type="published" when="2007-10-26">2007 Oct 26</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Disentangling the complexity of infectious diseases: Time is ripe to improve the first-line statistical toolbox for epidemiologists</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hanf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Gue ´gan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nacher</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.meegid.2013.09.006</idno>
		<idno type="PMID">24035791</idno>
	</analytic>
	<monogr>
		<title level="j">Infect Genet Evol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="497" to="505" />
			<date type="published" when="2014-01">2014 Jan</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Statistical methods for analyzing immunosignatures</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stafford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dinu</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2105-12-349</idno>
		<idno type="PMID">21854615</idno>
	</analytic>
	<monogr>
		<title level="j">BMC Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">349</biblScope>
			<date type="published" when="2011-08-19">2011 Aug 19</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Modelling pathways to Rubisco degradation: a structural equation network modelling approach</title>
		<author>
			<persName><forename type="first">C</forename><surname>Te ´tard-Jones</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Gatehouse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cooper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Leifert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rushton</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0087597</idno>
		<idno type="PMID">24498339</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">87597</biblScope>
			<date type="published" when="2014-02-03">2014 Feb 3</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Lederman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gianella</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11904-016-0297-9</idno>
		<idno type="PMID">26810437</idno>
	</analytic>
	<monogr>
		<title level="j">Curr HIV/AIDS Rep</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="10" to="19" />
			<date type="published" when="2016-02">2016 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Cytomegalovirus and HIV: A Dangerous Pas de Deux</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gianella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Letendre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">214</biblScope>
			<biblScope unit="issue">Suppl 2</biblScope>
			<biblScope unit="page" from="67" to="74" />
			<date type="published" when="2016-10-01">2016 Oct 1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lichtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cicconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Vita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cozzi-Lepri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Galli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lo</forename><surname>Caputo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1093/infdis/jiu417</idno>
		<idno type="PMID">25081936</idno>
	</analytic>
	<monogr>
		<title level="j">J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">211</biblScope>
			<biblScope unit="page" from="178" to="186" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">The silent war of CMV in aging and HIV infection</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Effros</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.mad.2015.09.003</idno>
		<idno type="PMID">26404009</idno>
	</analytic>
	<monogr>
		<title level="j">Mech Ageing Dev</title>
		<imprint>
			<biblScope unit="volume">158</biblScope>
			<biblScope unit="page" from="46" to="52" />
			<date type="published" when="2016-09">2016 Sep</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">CD8 T-cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Mudd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Shive</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Younes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Panigrahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Sieg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">HIV patients on antiretroviral therapy have high frequencies of CD8 T cells specific for Immediate Early protein-1 of cytomegalovirus</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Moss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>French</surname></persName>
		</author>
		<idno type="PMID">15802973</idno>
	</analytic>
	<monogr>
		<title level="j">AIDS</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="555" to="562" />
			<date type="published" when="2005-03-24">2005 Mar 24</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Tissue-resident memory T cells in cytomegalovirus infection</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Thom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oxenius</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.coviro.2016.01.014</idno>
		<idno type="PMID">26855038</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Virol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="63" to="69" />
			<date type="published" when="2016-02">2016 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals</title>
		<author>
			<persName><forename type="first">M</forename><surname>Abad-Fernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vallejo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hernandez-Novoa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Madrid</surname></persName>
		</author>
		<idno type="DOI">10.1097/QAI.0b013e31829a2f12</idno>
		<idno type="PMID">24047967</idno>
	</analytic>
	<monogr>
		<title level="j">J Acquir Immune Defic Syndr</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="149" to="153" />
			<date type="published" when="2013-10-01">2013 Oct 1</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Toll-like receptor signalling</title>
		<author>
			<persName><forename type="first">S</forename><surname>Akira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Takeda</surname></persName>
		</author>
		<idno type="DOI">10.1038/nri1391</idno>
		<idno type="PMID">15229469</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="499" to="511" />
			<date type="published" when="2004-07">2004 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Blocking TLR7-and TLR9-mediated IFN-alpha production by plasmacytoid dendritic cells does not diminish immune activation in early SIV infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Guiducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">R</forename><surname>Wonderlich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Normolle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Watkins</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.ppat.1003530</idno>
		<idno type="PMID">23935491</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS Pathog</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">1003530</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands</title>
		<author>
			<persName><forename type="first">A</forename><surname>Meier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Alter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Frahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sidhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bagchi</surname></persName>
		</author>
		<idno type="DOI">10.1128/JVI.00421-07</idno>
		<idno type="PMID">17507480</idno>
	</analytic>
	<monogr>
		<title level="j">J Virol</title>
		<imprint>
			<biblScope unit="volume">81</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="8180" to="8191" />
			<date type="published" when="2007-08">2007 Aug</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Bayesian methods for latent trait modelling of longitudinal data</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Dunson</surname></persName>
		</author>
		<idno type="DOI">10.1177/0962280206075309</idno>
		<idno type="PMID">17656454</idno>
	</analytic>
	<monogr>
		<title level="j">Stat Methods Med Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="399" to="415" />
			<date type="published" when="2007-10">2007 Oct</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Interferon-stimulated genes: a complex web of host defenses</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Chevillotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rice</surname></persName>
		</author>
		<idno type="DOI">10.1146/annurev-immunol-032713-120231</idno>
		<idno type="PMID">24555472</idno>
	</analytic>
	<monogr>
		<title level="j">Annu Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="513" to="545" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Interferon-stimulated genes and their antiviral effector functions</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Schoggins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rice</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.coviro.2011.10.008</idno>
		<idno type="PMID">22328912</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Virol</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="519" to="525" />
			<date type="published" when="2011-12">2011 Dec</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Immune activation in the course of HIV-1 infection: Causes, phenotypes and persistence under therapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Younas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Psomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Reynes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Corbeau</surname></persName>
		</author>
		<idno type="DOI">10.1111/hiv.12310</idno>
		<idno type="PMID">26452565</idno>
	</analytic>
	<monogr>
		<title level="j">HIV Med</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="89" to="105" />
			<date type="published" when="2016-02">2016 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Relationship between chronic hepatitis B and metabolic syndrome: A structural equation modeling approach</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1002/oby.21333</idno>
		<idno type="PMID">26719030</idno>
	</analytic>
	<monogr>
		<title level="j">Obesity</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="483" to="489" />
			<date type="published" when="2016-02">2016 Feb</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">A structural equation modelling approach to explore the role of B vitamins and immune markers in lung cancer risk</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">T</forename><surname>Baltar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Xun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ferrari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Relton</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10654-013-9793-z</idno>
		<idno type="PMID">23532743</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="677" to="688" />
			<date type="published" when="2013-08">2013 Aug</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Malignant Potential of Gastrointestinal Cancers Assessed by Structural Equation Modeling</title>
		<author>
			<persName><forename type="first">H</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Arimura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Onodera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Takahashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Okahara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kodaira</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0149327</idno>
		<idno type="PMID">26889682</idno>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">149327</biblScope>
			<date type="published" when="2016-02-18">2016 Feb 18</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Structural equation modeling of immunotoxicity associated with exposure to perfluorinated alkylates</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">B</forename><surname>Mogensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grandjean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Heilmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Nielsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Weihe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Budtz-Jørgensen</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12940-015-0032-9</idno>
		<idno type="PMID">26041029</idno>
	</analytic>
	<monogr>
		<title level="j">Environ Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">47</biblScope>
			<date type="published" when="2015-06-05">2015 Jun 5</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Applied immuno-epidemiological research: an approach for integrating existing knowledge into the statistical analysis of multiple immune markers</title>
		<author>
			<persName><forename type="first">B</forename><surname>Genser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Figueiredo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Alca ˆntara-Neves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Barreto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Cooper</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Immunol</title>
		<imprint>
			<date type="published" when="2016-05">2016 May</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Closing the gap on causal processes of infection risk from cross-sectional data: structural equation models to understand infection and co-infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Carver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Beatty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Troyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stutzman-Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">R</forename><surname>Barrs</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13071-015-1274-7</idno>
		<idno type="PMID">26701692</idno>
	</analytic>
	<monogr>
		<title level="j">Parasit Vectors</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">658</biblScope>
			<date type="published" when="2015-12-23">2015 Dec 23</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">HIV-associated chronic immune activation</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paiardini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mu ¨ller-Trutwin</surname></persName>
		</author>
		<idno type="DOI">10.1111/imr.12079</idno>
		<idno type="PMID">23772616</idno>
	</analytic>
	<monogr>
		<title level="j">Immunol Rev</title>
		<imprint>
			<biblScope unit="volume">254</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="78" to="101" />
			<date type="published" when="2013-07">2013 Jul</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
